Literature DB >> 16772865

Substance abuse and the management of medication nonadherence in schizophrenia.

Joshua Wilk1, Steven C Marcus, Joyce West, Lisa Countis, Rebecca Hall, Darrel A Regier, Mark Olfson.   

Abstract

To compare the clinical characteristics and psychiatric management of antipsychotic nonadherence among outpatients with schizophrenia who either do or do not have current or past comorbid substance use disorders, a national survey was conducted of psychiatrists engaged in the management of schizophrenia. Respondents reported on the presentation and management of one adult patient who had been under their care for at least 1 year and who had been nonadherent with oral antipsychotic medications at some point in the last year. The response rate was 69.3%. Patients with schizophrenia only (N = 190) were compared with patients with schizophrenia and a history of a co-occurring substance use disorder (N = 105). Approximately one third (35.6%) of antipsychotic nonadherent schizophrenia patients had a comorbid substance use disorder. Denial of illness was the most commonly cited primary reason for antipsychotic nonadherence. Psychiatrists were significantly less likely to discuss with comorbid patients than patients without comorbid substance use linkages between antipsychotic adherence and progress toward personal goals (64.5% vs. 78.9%), and significantly less likely to explore the meaning of taking medication to the patient's identity (59.2% vs. 73.3%). However, psychiatrists were approximately two times more likely to add another antipsychotic for patients with substance use disorders (22.8% vs. 11.0%). There were no perceived differences between the two groups in effectiveness of interventions to manage medication nonadherence. Comorbid substance use disorders are common among psychiatric outpatients with schizophrenia who are nonadherent with antipsychotic medications. Some psychological approaches tend to be used less often with patients with comorbid substance use disorders, although when they are used, psychiatrists report they are no less effective than they are for schizophrenia patients without comorbid substance use disorders. These findings suggest that some psychological interventions may tend to be underutilized in the management of medication nonadherence among patients with comorbid schizophrenia and substance use disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16772865     DOI: 10.1097/01.nmd.0000221289.54911.63

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  10 in total

Review 1.  Tactics and technologies to manage nonadherence in patients with schizophrenia.

Authors:  William M Glazer; Mathew J Byerly
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

2.  Predictors of medication non-adherence in Bulgarian outpatients with schizophrenia.

Authors:  Iglika Vassileva; Vihra Milanova; Turan Asan
Journal:  Community Ment Health J       Date:  2014-01-23

3.  Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies.

Authors:  Pál Czobor; Richard A Van Dorn; Leslie Citrome; Rene S Kahn; W Wolfgang Fleischhacker; Jan Volavka
Journal:  Eur Neuropsychopharmacol       Date:  2015-04-30       Impact factor: 4.600

4.  The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.

Authors:  Maju Mathew Koola; Heidi J Wehring; Deanna L Kelly
Journal:  J Dual Diagn       Date:  2012

5.  HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use.

Authors:  Geetanjali Chander; Seth Himelhoch; John A Fleishman; James Hellinger; Paul Gaist; Richard D Moore; Kelly A Gebo
Journal:  AIDS Care       Date:  2009-05

6.  Factors associated with medication non-adherence among patients with severe mental disorder - A cross sectional study in a tertiary care centre.

Authors:  Papiya Ghosh; Sivaprakash Balasundaram; Avudaiappan Sankaran; Vigneshvar Chandrasekaran; Sukanto Sarkar; Sunayana Choudhury
Journal:  Explor Res Clin Soc Pharm       Date:  2022-09-12

7.  Perspectives on reasons for non-adherence to medication in persons with schizophrenia in Ethiopia: a qualitative study of patients, caregivers and health workers.

Authors:  Solomon Teferra; Charlotte Hanlon; Teferra Beyero; Lars Jacobsson; Teshome Shibre
Journal:  BMC Psychiatry       Date:  2013-06-17       Impact factor: 3.630

8.  Design paper: The CapOpus trial: a randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis.

Authors:  Carsten Hjorthøj; Allan Fohlmann; Anne-Mette Larsen; Mette T R Madsen; Lone Vesterager; Christian Gluud; Mikkel C Arendt; Merete Nordentoft
Journal:  Trials       Date:  2008-07-11       Impact factor: 2.279

9.  Incidence and factors associated with medication nonadherence in patients with mental illness: a cross-sectional study.

Authors:  J M Lucca; M Ramesh; G Parthasarathi; D Ram
Journal:  J Postgrad Med       Date:  2015 Oct-Dec       Impact factor: 1.476

10.  Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life.

Authors:  Ilaria Cuomo; Georgios D Kotzalidis; Simone de Persis; Daria Piacentino; Filippo Perrini; Emanuela Amici; Sergio De Filippis
Journal:  Neuropsychiatr Dis Treat       Date:  2018-06-21       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.